{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:01Z","timestamp":1792785841407,"version":"4.5.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Military Infectious Disease Research Program"},{"name":"President\u2019s Emergency Plan"},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-11-2-0174"],"award-info":[{"award-number":["W81XWH-11-2-0174"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-2-0040"],"award-info":[{"award-number":["W81XWH-18-2-0040"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Emerging HIV drug resistance (HIVDR) could jeopardize the success of standardized HIV management protocols in resource-limited settings. We characterized HIVDR among antiretroviral therapy (ART)-naive and experienced participants in the African Cohort Study (AFRICOS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From January 2013 to April 2019, adults with HIV-1 RNA &amp;gt;1000 copies\/mL underwent ART history review and HIVDR testing upon enrollment at 12 clinics in Uganda, Kenya, Tanzania, and Nigeria. We calculated resistance scores for specific drugs and tallied major mutations to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), and protease inhibitors (PIs) using Stanford HIVDB 8.8 and SmartGene IDNS software. For ART-naive participants, World Health Organization surveillance drug resistance mutations (SDRMs) were noted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HIVDR testing was performed on 972 participants with median age 35.7 (interquartile range [IQR] 29.7\u201342.7) years and median CD4 295 (IQR 148\u2013478) cells\/mm3. Among 801 ART-naive participants, the prevalence of SDRMs was 11.0%, NNRTI mutations 8.2%, NRTI mutations 4.7%, and PI mutations 0.4%. Among 171 viremic ART-experienced participants, NNRTI mutation prevalence was 83.6%, NRTI 67.8%, and PI 1.8%. There were 90 ART-experienced participants with resistance to both efavirenz and lamivudine, 33 (36.7%) of whom were still prescribed these drugs. There were 10 with resistance to both tenofovir and lamivudine, 8 (80.0%) of whom were prescribed these drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Participants on failing ART regimens had a high burden of HIVDR that potentially limited the efficacy of standardized first- and second-line regimens. Management strategies that emphasize adherence counseling while delaying ART switch may promote drug resistance and should be reconsidered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1161","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T15:39:11Z","timestamp":1596814751000},"page":"e2311-e2322","source":"Crossref","is-referenced-by-count":47,"title":["Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5947-265X","authenticated-orcid":false,"given":"Trevor A","family":"Crowell","sequence":"first","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brook","family":"Danboise","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Parikh","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allahna","family":"Esber","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Dear","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Coakley","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kasembeli","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"HJF Medical Research International, Kericho, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah","family":"Maswai","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"HJF Medical Research International, Kericho, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samoel","family":"Khamadi","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"HJF Medical Research International, Mbeya, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bahemana","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"HJF Medical Research International, Mbeya, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Iroezindu","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"HJF Medical Research International, Abuja, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Kiweewa","sequence":"additional","affiliation":[{"name":"Makerere University Walter Reed Project, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Owuoth","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"HJF Medical Research International, Kisumu, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Freeman","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda L","family":"Jagodzinski","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A","family":"Malia","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh Ann","family":"Eller","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sodsai","family":"Tovanabutra","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila A","family":"Peel","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A","family":"Ake","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina S","family":"Polyak","sequence":"additional","affiliation":[{"name":"US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA"},{"name":"Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"AFRICOS Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"2021100522223393800_CIT0001","author":"Joint United Nations Programme on HIV\/AIDS"},{"key":"2021100522223393800_CIT0002","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1377\/hlthaff.2018.05391","article-title":"Twenty years of antiretroviral therapy for people living with hiv: global costs, health achievements, economic benefits","volume":"38","author":"Forsythe","year":"2019","journal-title":"Health Aff (Millwood)"},{"key":"2021100522223393800_CIT0003","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix089","article-title":"Impact of HIV drug resistance on HIV\/AIDS-associated mortality, new infections, and antiretroviral therapy program costs in Sub-Saharan Africa","volume":"215","author":"Phillips","year":"2017","journal-title":"J Infect Dis"},{"key":"2021100522223393800_CIT0004","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1093\/cid\/cis206","article-title":"Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004\u20132011","volume":"54","author":"Jordan","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2021100522223393800_CIT0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/135965350801302S04","article-title":"Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment","volume":"13","author":"Bennett","year":"2008","journal-title":"Antivir Ther"},{"key":"2021100522223393800_CIT0006","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/S1473-3099(17)30482-6","article-title":"The WHO public health approach to HIV treatment and care: looking back and looking ahead","volume":"18","author":"Ford","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021100522223393800_CIT0007","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"2021100522223393800_CIT0008","first-page":"221","article-title":"Implementing HIV-1 genotypic resistance testing in antiretroviral therapy programs in Africa: needs, opportunities, and challenges","volume":"15","author":"Lessells","year":"2013","journal-title":"AIDS Rev"},{"key":"2021100522223393800_CIT0009","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/infdis\/jit107","article-title":"Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings","volume":"207","author":"Hosseinipour","year":"2013","journal-title":"J Infect Dis"},{"key":"2021100522223393800_CIT0010","volume-title":"National guidelines for the management of HIV and AIDS: sixth edition","author":"National AIDS Control Programme","year":"2017"},{"key":"2021100522223393800_CIT0011","volume-title":"National guidelines for HIV prevention treatment and care","author":"National AIDS and STI\u2019s Control Programme","year":"2016"},{"key":"2021100522223393800_CIT0012","volume-title":"Guidelines on use of antiretroviral drugs for treating and preventing HIV Infection in Kenya\u20142018 Edition","author":"National AIDS and STI Control Program","year":"2018"},{"key":"2021100522223393800_CIT0013","volume-title":"Consolidated guidelines for prevention and treatment of HIV in Uganda","author":"Ministry of Health","year":"2018"},{"key":"2021100522223393800_CIT0014","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1097\/QAD.0000000000002234","article-title":"Simplifying switch to second-line antiretroviral therapy in sub-Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure","volume":"33","author":"Shroufi","year":"2019","journal-title":"AIDS"},{"key":"2021100522223393800_CIT0015","doi-asserted-by":"crossref","first-page":"e1007083","DOI":"10.1371\/journal.pcbi.1007083","article-title":"Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: modelling the spread of resistance in South Africa","volume":"15","author":"Hauser","year":"2019","journal-title":"PLoS Comput Biol"},{"key":"2021100522223393800_CIT0016","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/cid\/ciy981","article-title":"Noninfectious comorbidity in the African cohort study","volume":"69","author":"Ake","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021100522223393800_CIT0017","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"2021100522223393800_CIT0018","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/aje\/kwh090","article-title":"A modified poisson regression approach to prospective studies with binary data","volume":"159","author":"Zou","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2021100522223393800_CIT0019","volume-title":"Guidelines on the public health response to pretreatment HIV drug resistance","author":"World Health Organization","year":"2017"},{"key":"2021100522223393800_CIT0020","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/QAI.0b013e3182618f05","article-title":"Prevalence of transmitted antiretroviral drug resistance differs between acutely and chronically HIV-infected patients","volume":"61","author":"Yanik","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021100522223393800_CIT0021","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/infdis\/jiq167","article-title":"Differential persistence of transmitted HIV-1 drug resistance mutation classes","volume":"203","author":"Jain","year":"2011","journal-title":"J Infect Dis"},{"key":"2021100522223393800_CIT0022","doi-asserted-by":"crossref","first-page":"vex008","DOI":"10.1093\/ve\/vex008","article-title":"Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network","volume":"3","author":"Wertheim","year":"2017","journal-title":"Virus Evol"},{"key":"2021100522223393800_CIT0023","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/JVI.75.11.4999-5008.2001","article-title":"Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy","volume":"75","author":"Bacheler","year":"2001","journal-title":"J Virol"},{"key":"2021100522223393800_CIT0024","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jac\/dkt316","article-title":"Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing","volume":"69","author":"Melikian","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2021100522223393800_CIT0025","volume-title":"Update of recommendations on first- and second-line antiretroviral regimens","author":"World Health Organization","year":"2019"},{"key":"2021100522223393800_CIT0026","volume-title":"WHO global strategy for the surveillance and monitoring of HIV drug resistance 2012","author":"World Health Organization","year":"2012"},{"key":"2021100522223393800_CIT0027","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3851\/IMP2437","article-title":"Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review","volume":"18","author":"Stadeli","year":"2013","journal-title":"Antivir Ther"},{"key":"2021100522223393800_CIT0028","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021100522223393800_CIT0029","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1089\/aid.2011.0367","article-title":"Prevalence of drug resistance mutations and HIV type 1 subtypes in an HIV type 1-infected cohort in rural Tanzania","volume":"29","author":"Masimba","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2021100522223393800_CIT0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/135965350801302S08","article-title":"Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania","volume":"13","author":"Somi","year":"2008","journal-title":"Antivir Ther"},{"key":"2021100522223393800_CIT0031","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3851\/IMP3342","article-title":"Transmitted, pre-treatment and acquired antiretroviral drug resistance among men who have sex with men and transgender women living with HIV in Nigeria","volume":"24","author":"Crowell","year":"2019","journal-title":"Antivir Ther"},{"key":"2021100522223393800_CIT0032","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S1473-3099(11)70149-9","article-title":"HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study","volume":"11","author":"Hamers","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2021100522223393800_CIT0033","first-page":"1749","article-title":"Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa","volume":"61","author":"Boender","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021100522223393800_CIT0034","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1097\/QAD.0000000000001110","article-title":"Increasing HIV-1 pretreatment drug resistance among antiretroviral-naive adults initiating treatment between 2006 and 2014 in Nairobi, Kenya","volume":"30","author":"Chung","year":"2016","journal-title":"AIDS"},{"key":"2021100522223393800_CIT0035","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/infdis\/jix544","article-title":"Prevalence of pre-antiretroviral-treatment drug resistance by gender, age, and other factors in HIV-infected individuals initiating therapy in Kenya, 2013\u20132014","volume":"216","author":"Silverman","year":"2017","journal-title":"J Infect Dis"},{"key":"2021100522223393800_CIT0036","first-page":"3","article-title":"Update on HIV-1 acquired and transmitted drug resistance in Africa","volume":"17","author":"Ssemwanga","year":"2015","journal-title":"AIDS Rev"},{"key":"2021100522223393800_CIT0037","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0000000000001660","article-title":"Twenty-five years of lamivudine: current and future use for the treatment of HIV-1 infection","volume":"78","author":"Quercia","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021100522223393800_CIT0038","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1126\/science.7542804","article-title":"Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy","volume":"269","author":"Larder","year":"1995","journal-title":"Science"},{"key":"2021100522223393800_CIT0039","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/j.1460-2075.1996.tb00777.x","article-title":"Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme","volume":"15","author":"Back","year":"1996","journal-title":"EMBO J"},{"key":"2021100522223393800_CIT0040","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJM199512213332502","article-title":"Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party","volume":"333","author":"Eron","year":"1995","journal-title":"N Engl J Med"},{"key":"2021100522223393800_CIT0041","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/00002030-199610090-00007","article-title":"Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients","volume":"10","author":"Kuritzkes","year":"1996","journal-title":"AIDS"},{"key":"2021100522223393800_CIT0042","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1126\/science.271.5253.1282","article-title":"Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase","volume":"271","author":"Wainberg","year":"1996","journal-title":"Science"},{"key":"2021100522223393800_CIT0043","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/infdis\/jiz631","article-title":"HIV-1 viral load is elevated in individuals with reverse transcriptase mutation M184V\/I during virological failure of first line antiretroviral therapy and is associated with compensatory mutation L74I","volume":"222","author":"Gregson","year":"2020","journal-title":"J Infect Dis"},{"key":"2021100522223393800_CIT0044","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"Paton","year":"2014","journal-title":"N Engl J Med"},{"key":"2021100522223393800_CIT0045","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/S0140-6736(13)61164-2","article-title":"Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study","volume":"381","author":"Second-Line Study Group","year":"2013","journal-title":"Lancet"},{"key":"2021100522223393800_CIT0046","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1473-3099(17)30630-8","article-title":"Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial","volume":"18","author":"Hakim","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2021100522223393800_CIT0047","volume-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2019"},{"key":"2021100522223393800_CIT0048","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society-USA Panel","volume":"68","author":"Gunthard","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021100522223393800_CIT0049","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/cid\/ciu003","article-title":"A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York City","volume":"58","author":"Gagliardo","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021100522223393800_CIT0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3851\/IMP1719","article-title":"Virological characterization of patients failing darunavir\/ritonavir or lopinavir\/ritonavir treatment in the ARTEMIS study: 96-week analysis","volume":"16","author":"Lathouwers","year":"2011","journal-title":"Antivir Ther"},{"key":"2021100522223393800_CIT0051","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3851\/IMP1745","article-title":"Nevirapine versus atazanavir\/ritonavir, each combined with tenofovir disoproxil fumarate\/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial","volume":"16","author":"Soriano","year":"2011","journal-title":"Antivir Ther"},{"key":"2021100522223393800_CIT0052","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/cid\/ciz372","article-title":"Clinical impact and cost-effectiveness of genotype testing at human immunodeficiency virus diagnosis in the United States","volume":"70","author":"Hyle","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021100522223393800_CIT0053","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/cid\/cix542","article-title":"Should we be testing for baseline integrase resistance in patients newly diagnosed with human immunodeficiency virus?","volume":"65","author":"Koullias","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2021100522223393800_CIT0054","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/S2352-3018(18)30317-5","article-title":"Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study","volume":"6","author":"Phillips","year":"2019","journal-title":"Lancet HIV"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1161\/34900881\/ciaa1161.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e2311\/40511643\/ciaa1161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e2311\/40511643\/ciaa1161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T01:46:07Z","timestamp":1667699167000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/7\/e2311\/5891786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":54,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,8,12]]},"published-print":{"date-parts":[[2021,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1161","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2020,8,12]]}}}